Cheap Wegovy Alternative 2026: Compounded Semaglutide from $99/Month

What Makes Wegovy Different from Other Semaglutide Products

Wegovy, Ozempic, and compounded semaglutide all contain the same active molecule: semaglutide. The differences between them are regulatory, commercial, and presentational rather than pharmacological.

Ozempic is approved by the FDA specifically for type 2 diabetes management at doses up to 2mg. Wegovy is the same semaglutide formulation approved for chronic weight management at doses up to 2.4mg. Novo Nordisk received a separate FDA approval for Wegovy, which allowed them to market it specifically for obesity — and to price it at a premium over Ozempic.

Both drugs use Novo Nordisk's proprietary auto-injector pen, their stabilizing excipients, and their manufacturing infrastructure. Compounded semaglutide bypasses all of this. A licensed compounding pharmacy takes pharmaceutical-grade semaglutide API (active pharmaceutical ingredient), prepares it in the prescribed concentration, and fills it into vials for subcutaneous injection with a standard syringe. The semaglutide molecule that enters your bloodstream is chemically identical.

Wegovy's specific approval for obesity is valuable from a regulatory and coverage perspective — it is the labeling that allows insurers to cover it for obesity rather than only diabetes. But it does not make the semaglutide in Wegovy clinically superior to the semaglutide in compounded preparations. The molecule is the molecule.

Compounded Semaglutide: How the $99 Price Is Possible

The compounding model eliminates the cost layers that make Wegovy so expensive. When Novo Nordisk sells Wegovy, the price reflects their R&D investment, patent protection, FDA approval costs, branded marketing spend, the auto-injector device, and the margins of wholesalers, pharmacy benefit managers, and retail pharmacies. Each layer adds cost.

Compounding pharmacies buy pharmaceutical-grade semaglutide API from verified suppliers and prepare it on a per-prescription basis. There is no marketing budget, no proprietary device, no brand premium. The compounding pharmacy charges for their labor, materials, and quality controls. Trimi's streamlined telehealth model means provider costs are distributed efficiently across a large patient base. The result: $99 per month for a medication that is therapeutically equivalent.

For a detailed breakdown of the economics, see our guide to why compounded semaglutide costs $99 instead of $1,349. The full picture of compounding economics explains why quality and price are not inversely related in this case.

Insurance and Wegovy: The Real Coverage Picture

Novo Nordisk's savings card can reduce Wegovy's cost for commercially insured patients whose plans cover it, but the coverage landscape remains complicated. As of 2026:

• Medicare Part D does not cover weight loss medications under current law, including Wegovy, even with a separate obesity indication
• Medicaid coverage varies by state — most states do not cover obesity medications, though a small number have expanded coverage
• Commercial insurance covers Wegovy inconsistently — many plans exclude it, require prior authorization, or impose step therapy requirements that can take months to complete
• Even insured patients who get coverage approved often face high deductibles or co-pays that reduce but do not eliminate cost
• Insurance coverage can be revoked at the next plan year's formulary update without notice

Trimi's compounded semaglutide program sidesteps all of this. There is no insurance required, no prior authorization, no formulary review, and no coverage appeal process. The $99 monthly price is available to any eligible patient regardless of insurance status. For the millions of Americans on Medicare, Medicaid, or plans that exclude obesity medications, this is often the only genuinely affordable pathway to semaglutide treatment.

Starting Compounded Semaglutide Through Trimi

Getting started with compounded semaglutide at Trimi takes three steps: complete the health assessment, get approved, receive your medication. The entire process is online and typically takes one to two weeks from first registration to first injection.

For a more detailed walk-through of getting started, including what to expect at each dose level and how to manage early side effects, see our quick-start guide to getting your first dose. If you have questions about timeline, the same-day consultation guide covers how fast the process can move.

Dose Titration: Wegovy vs Compounded Semaglutide

Wegovy follows a standard titration schedule designed to minimize gastrointestinal side effects during dose escalation. The same titration logic applies to compounded semaglutide. Your Trimi provider will prescribe doses that follow this standard protocol:

Patients transitioning from Wegovy continue at their current dose. There is no need to restart titration. Your Trimi provider confirms the appropriate compounded dose for your specific point in the titration schedule.

What Results to Expect

Semaglutide produces clinically significant weight loss in the majority of patients. In the STEP 1 trial, 86.4% of patients treated with semaglutide 2.4mg achieved at least 5% body weight loss, 69.1% achieved at least 10%, and 50.5% achieved at least 15%. Average weight loss was 14.9% over 68 weeks — about 33 pounds for someone starting at 220 pounds.

Results vary by individual. Patients with type 2 diabetes tend to lose less weight than those without (consistent with STEP 2 data). Higher body weight at baseline, younger age, and consistent lifestyle support tend to be associated with better outcomes. Weight loss typically plateaus around months six to twelve at the maintenance dose.

Most patients notice appetite suppression within the first two weeks. Measurable weight loss is usually apparent by weeks four to six. The full effect develops over six to twelve months of treatment. For guidance on supporting your results, see our anti-inflammatory diet guide for GLP-1 users.